The Gene Discovery Shared Resource consists of three separate but interactive cores: 1) the Family Ascertainment Core (run and directed by Dr. Daniel Schaid); 2) the Genotyping Core (run and directed by Drs. Stephen Thibodeau and Rebecca Berry); and 3) the Gene Identification and Mutation Detection Core (run and directed by Drs. David Smith and Wanguo Liu). These three Cores are logical extensions of one another and are intended to provide help and expertise to members of the Cancer Center on various aspects of using modern genetic analyses to localize, identify and characterize genes that are important in both familial and sporadic cancer development. The three cores are directed by experts in their field and are organized as one shared resource to maximize the interaction among the three. They are both conceptually and physically (laboratories and study coordinators are adjacent to each other) inter-related. Although many Cancer Center members have expertise in some of these areas, no single laboratory has expertise in all. The general strategy is that epidemiologic data and biological specimens are collected through the resources available in the Family Ascertainment Core and the Tissue Procurement Shared Resource. The DNA collected can be studies with linkage or association analyses through the resources of the Genotyping Core, and then the actual genes can be sought, identified, and characterized in the Gene Identification and Mutation Detection Core Laboratory.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015083-25S3
Application #
6396749
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1999-05-27
Project End
2000-02-29
Budget Start
Budget End
Support Year
25
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications